Balancing perioperative risks in orthopedic surgery: The patient with a coronary stent

Orthopedics

Volumn 30, Issue 11, 2007, Pages 931-936

  Murphy, J Thomas ^a,b   Fahy, Brenda G ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN; PACLITAXEL; RAPAMYCIN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; CARDIOLOGIST; CELL CYCLE ARREST; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG ELUTING STENT; EPIDURAL ANESTHESIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIOPERATIVE PERIOD; RESTENOSIS; REVIEW; RISK ASSESSMENT; SEPSIS; SPINAL ANESTHESIA; ST SEGMENT ELEVATION; SURGICAL PATIENT; SURGICAL RISK; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; TREATMENT WITHDRAWAL; STENT;

ANESTHESIA, EPIDURAL; ANESTHESIA, SPINAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; STENTS;

EID: 38349133425     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20071101-04     Document Type: Review

References (42)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl):338s-400s.
2. Oh JO, Robon MJ, Akers WS. Optimizing antiplatelet and anticoagulant agents in the perioperative orthopedic surgery patient. Orthopedics. 2005; 28:453-458.
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113:e166-286.
4. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation. 1994; 90:908-914.
5. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH: CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102:624-629.
6. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323.
7. Salam AM, Al Suwaidi J, Holmes DR Jr. Drug-eluting coronary stents. Curr Probl Cardiol. 2006; 31:8-119.
8. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006; 27:166-170.
9. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000; 35:1288-1294.
10. Smith SC, Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001; 37:2215-2238.
11. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006; 355:1105-1113.
12. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006; 11:1093-1104.
13. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115:813-818.
14. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery - a prosective outcome study. Br J Anaesth. 2006; 96:686-693.
15. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293:2126-2130.
16. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004; 110:2361-2367.
17. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005; 45:456-459.
18. Fléron MH, Dupuis M, Mottet P, Le Feuvre C, Godet G. Non cardiac surgery in patient with coronary stenting: think sirolimus now! [in French]. Ann Fr Anesth Reanim. 2003; 22:733-735.
19. Decoene C, Vincentelli A, Fabre O, Crepin F, Pol A. Late thrombosis of a drug-eluting coronary stent after antiplatelet therapy discontinuation [in French]. Ann Fr Anesth Reanim. 2005; 24:1275-1277.
20. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364:1519-1521.
21. Stabile E, Cheneau E, Kinnaird T, et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med. 2004; 5:173-176.
22. Murphy JT, Fahy BG. Thrombosis of sirolimus-eluting coronary stent in the post-anesthesia care unit. Anesth Analg. 2005; 101:971-973.
23. Reich DL, Patel GC, Vela-Cantos F, Bodian C, Lansman S. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg. 1994; 79:4-8.
24. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004; 78:1536-1541.
25. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004; 128:425-431.
26. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med. 2005; 257:399-414.
27. Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005; 61:189-194
28. Ferraris VF, Ferraris SP, Moliterno DJ, et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg. 2005; 79:1454-1461.
29. Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication before cataract surgery. Ophthalmology. 2003; 110:1784-1788.
30. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in arterial disease. Consensus statement. Eur J Vasc Endovasc Surg. 2003; 26:1-16.
31. Lehot JJ, Piriou V, Durand de Giveney G, Coriat P. Patient at risk of endocoronary stent thrombosis during perioperative period: a frequent situation [in French]. Ann Fr Anesth Reanim. 2005; 24:1247-1249.
32. Albaladejo P, Marret E, Piriou V, Samama CM; French Society of Anesthesiology and Intensive Care. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth. 2006; 97:580-582.
33. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006; 354:483-495.
34. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004; 147:463-467.
35. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-1302.
36. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Reaistry. Chest. 2003; 124(6 suppl):349s-356s.
37. Callaghan JJ, Dorr LD, Engh GA, et al. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians-are they appropriate for orthopaedic surgery? J Arthroplasty. 2005; 20:273-274.
38. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006; 452:175-180.
39. Sharrock NE, Cazan MG, Hargett MJ, Williams-Russo P, Wilson PD Jr. Changes in mortality after total hip and knee arthroplasty over a ten-year period. Anesth Analg. 1995; 80:242-248.
40. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003; 99:552-560
41. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003; 28:172-197.
42. Klein SM, D'Ercole F, Greengrass RA, Warner DSl. Enoxaparin associated with psoas hematoma and lumbar plexopathy after lumbar plexus block. Anesthesiology. 1997; 87:1576-1579.